TY - JOUR
T1 - Bridging to a Long-Term Ventricular Assist Device With Short-Term Mechanical Circulatory Support
AU - Kurihara, Chitaru
AU - Kawabori, Masashi
AU - Sugiura, Tadahisa
AU - Critsinelis, Andre C.
AU - Wang, Suwei
AU - Cohn, William E.
AU - Civitello, Andrew B.
AU - Frazier, O. H.
AU - Morgan, Jeffrey A.
N1 - Publisher Copyright:
© 2018 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
PY - 2018/6
Y1 - 2018/6
N2 - Implanting short-term mechanical circulatory support (MCS) devices as a bridge-to-decision is increasingly popular. However, outcomes have not been well studied in patients who receive short-term MCS before receiving long-term left ventricular assist device (LVAD) support. We analyzed outcomes in our single-center experience with long-term continuous-flow (CF)-LVAD recipients with pre-implantation short-term MCS. From November 2003 through March 2016, 526 patients (mean age, 54.7 ± 13.5 years) with chronic heart failure (mean ejection fraction, 21.7 ± 3.6%) underwent implantation of either the HeartMate II (n = 403) or the HeartWare device (n = 123). Before implantation, 269 patients received short-term MCS with the TandemHeart, the Impella 2.5/5.0, an intra-aortic balloon pump (IABP), venoarterial extracorporeal membrane oxygenation (VA-ECMO), or the CentriMag. The short-term MCS patients were compared with the CF-LVAD–only patients regarding preoperative demographics, incidence of postoperative complications, and long-term survival. The 269 patients received the following short-term MCS devices: 57 TandemHeart, 27 Impella, 172 IABP, 12 VA-ECMO, and 1 CentriMag. Survival at 30 days, 6 months, 1 year, and 2 years was 94.2, 87.2, 79.4, and 72.4%, respectively, for CF-LVAD–only patients versus 91.0, 78.1, 73.4, and 65.6%, respectively, for short-term MCS + CF-LVAD patients (P = 0.17). Within the short-term MCS group, survival at 24 months was poorest for patients supported with VA-ECMO or the TandemHeart (P = 0.03 for both), and survival across all four time points was poorest for patients supported with VA-ECMO (P = 0.02). Short-term MCS was not an independent predictor of mortality in multivariate Cox regression models (hazard ratio = 1.12, 95% confidence interval = 0.84–1.49, P = 0.43). In conclusion, we found that using short-term MCS therapy—except for VA-ECMO—as a bridge to long-term CF-LVAD support was not associated with poorer survival.
AB - Implanting short-term mechanical circulatory support (MCS) devices as a bridge-to-decision is increasingly popular. However, outcomes have not been well studied in patients who receive short-term MCS before receiving long-term left ventricular assist device (LVAD) support. We analyzed outcomes in our single-center experience with long-term continuous-flow (CF)-LVAD recipients with pre-implantation short-term MCS. From November 2003 through March 2016, 526 patients (mean age, 54.7 ± 13.5 years) with chronic heart failure (mean ejection fraction, 21.7 ± 3.6%) underwent implantation of either the HeartMate II (n = 403) or the HeartWare device (n = 123). Before implantation, 269 patients received short-term MCS with the TandemHeart, the Impella 2.5/5.0, an intra-aortic balloon pump (IABP), venoarterial extracorporeal membrane oxygenation (VA-ECMO), or the CentriMag. The short-term MCS patients were compared with the CF-LVAD–only patients regarding preoperative demographics, incidence of postoperative complications, and long-term survival. The 269 patients received the following short-term MCS devices: 57 TandemHeart, 27 Impella, 172 IABP, 12 VA-ECMO, and 1 CentriMag. Survival at 30 days, 6 months, 1 year, and 2 years was 94.2, 87.2, 79.4, and 72.4%, respectively, for CF-LVAD–only patients versus 91.0, 78.1, 73.4, and 65.6%, respectively, for short-term MCS + CF-LVAD patients (P = 0.17). Within the short-term MCS group, survival at 24 months was poorest for patients supported with VA-ECMO or the TandemHeart (P = 0.03 for both), and survival across all four time points was poorest for patients supported with VA-ECMO (P = 0.02). Short-term MCS was not an independent predictor of mortality in multivariate Cox regression models (hazard ratio = 1.12, 95% confidence interval = 0.84–1.49, P = 0.43). In conclusion, we found that using short-term MCS therapy—except for VA-ECMO—as a bridge to long-term CF-LVAD support was not associated with poorer survival.
KW - Left ventricular assist device
KW - —Long-term
KW - —Mechanical circulatory support
KW - —Outcomes
KW - —Short-term
UR - http://www.scopus.com/inward/record.url?scp=85042391280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042391280&partnerID=8YFLogxK
U2 - 10.1111/aor.13112
DO - 10.1111/aor.13112
M3 - Article
C2 - 29473181
AN - SCOPUS:85042391280
SN - 0160-564X
VL - 42
SP - 589
EP - 596
JO - Artificial Organs
JF - Artificial Organs
IS - 6
ER -